BioSpace News Archive

Insights into the workings of an immune cell surface receptor, called PD-1, reveal how treatments that restrict its action can potentially be strengthened to improve their anticancer effect, a new study shows.

Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight.

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Wegovy® to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight along with a reduced calorie diet and increased physical activity.

Soleno Therapeutics, Inc. announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to five new employees.

Anika Therapeutics, Inc., a global joint preservation company in early intervention orthopedics, announced that on March 1, 2024, Anika granted non-statutory stock options covering an aggregate of 2,500 shares of common stock at a per share exercise price of $25.14, which equaled the closing price of common stock on the Nasdaq Global Select Market on the grant date, to one newly hired non-executive employee.

Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023.

Structure Therapeutics Inc. (NASDAQ: GPCR) today announced that Raymond Stevens, Ph.D., the Company’s Founder and Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, 2024, at 8:00 AM ET in Miami, Florida.

Castle Biosciences, Inc. (Nasdaq: CSTL) today announced that it will share data across its dermatologic portfolio of gene expression profile (GEP) tests via oral and electronic poster presentations at the 2024 AAD Annual Meeting, taking place March 8-12 in San Diego.

Graphite Bio, Inc. announced that its Board of Directors has declared a special dividend in connection with the previously announced merger with Lenz Therapeutics, Inc. pursuant to the Agreement and Plan of Merger, dated November 14, 2023.

DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at Barclays Global Healthcare Conference 2024 on Wednesday, March 13, 2024, at 8:00 a.m. EDT.